Microbot Medical (NASDAQ:MBOT) Issues Earnings Results

Key Points

• Microbot Medical met earnings expectations, reporting a quarterly loss of $0.08 per share, but revenue of $0.24 million fell short of the $0.33 million analyst consensus.
• Shares declined 13.4% to $1.68 following the results, near the company’s $1.60 one-year low. The stock has a market capitalization of approximately $112.5 million.
• Analyst sentiment remains mixed but leans positive, with a consensus “Buy” rating and an average price target of $6.62; institutional investors own 16.3% of the company.

Microbot Medical (NASDAQ:MBOT - Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08), FiscalAI reports. The firm had revenue of $0.24 million during the quarter, compared to analysts' expectations of $0.33 million.

Microbot Medical Stock Down 13.4%

Shares of Microbot Medical stock traded down $0.26 on Tuesday, reaching $1.68. 891,568 shares of the company were exchanged, compared to its average volume of 1,525,497. The stock's 50 day moving average price is $1.83 and its 200-day moving average price is $2.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 22.59 and a quick ratio of 21.93. Microbot Medical has a 1-year low of $1.60 and a 1-year high of $4.67. The company has a market cap of $112.51 million, a P/E ratio of -6.44 and a beta of 1.06.

Wall Street Analyst Weigh In

MBOT has been the subject of a number of research reports. Loop Capital set a $4.00 price objective on Microbot Medical in a research note on Wednesday, June 3rd. Zacks Research raised Microbot Medical from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, July 22nd. HC Wainwright reiterated a "buy" rating on shares of Microbot Medical in a research note on Tuesday, July 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Microbot Medical in a research note on Wednesday, July 8th. Finally, Wall Street Zen upgraded shares of Microbot Medical from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $6.62.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MBOT. Virtu Financial LLC acquired a new stake in shares of Microbot Medical in the 4th quarter valued at $117,000. Invesco Ltd. purchased a new position in shares of Microbot Medical in the 4th quarter valued at about $49,000. XTX Topco Ltd purchased a new stake in Microbot Medical during the fourth quarter worth approximately $63,000. Man Group plc purchased a new position in Microbot Medical in the fourth quarter valued at approximately $35,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Microbot Medical during the fourth quarter worth approximately $222,000. Institutional investors and hedge funds own 16.30% of the company's stock.

About Microbot Medical

Microbot Medical Inc NASDAQ: MBOT is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source